This Article Full Text (PDF) References Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via Google Scholar Citing Articles via Scopus Google Scholar Articles by Mcguire, D. K Articles by Szczepaniak, L. S Search for Related Content PubMed PubMed Citation Articles by Mcguire, D. K Articles by Szczepaniak, L. S Social Bookmarking                         What's this?

The effect of rosiglitazone on integrated cardiovascular performance, cardiac structure, function and myocardial triglyceride: trial design and rationale

Department of Internal Medicine, the University of Texas Southwestern Medical Center, Dallas, Texas, US.

Raphael See

Division of Cardiology, Vanderbilt University, Nashville, Tennessee, 37240, US.

Shuaib M Abdullah

Department of Internal Medicine, the University of Texas Southwestern Medical Center, Dallas, Texas, US.

Peter G Snell

Department of Internal Medicine, the University of Texas Southwestern Medical Center, Dallas, Texas, US.

Jonathan M Mcgavock

Department of Internal Medicine, the University of Texas Southwestern Medical Center, Dallas, Texas, US.

Colby R Ayers

Department of Clinical Sciences, University of Texas Southwestern Medical Center, Dallas, Texas, US.

Lidia S Szczepaniak

Department of Internal Medicine, the University of Texas Southwestern Medical Center, Dallas, Texas, US.

The thiazolidinedione (TZD) class of medications has been associated with increased risk for peripheral oedema, as well as incident and worsening heart failure (HF). The mechanism of these observed effects remains unclear. Here we present the rationale and study design for a randomised clinical trial designed to evaluate the cardiac effects of rosiglitazone on integrated cardiovascular performance, cardiac structure and function.

The study is a randomised, single-centre, double-blind, placebo-controlled, parallel-group clinical trial to evaluate the effect of rosiglitazone on integrated cardiovascular performance in a cohort of patients with type 2 diabetes mellitus (T2DM) at increased risk for developing heart failure (HF). Participants will be randomised to receive rosiglitazone or matching placebo for six months. All subjects will undergo maximal treadmill cardiopulmonary exercise testing at baseline and after six months on study drug, with the primary trial end point of peak oxygen uptake indexed to fat-free mass (VO_2peak-FFM). Approximately two-thirds of the study cohort will undergo cardiac magnetic resonance imaging (MRI) and spectroscopy (MRS) at baseline and after six months of study therapy to assess cardiac structure, function and myocardial triglyceride content.

While concerns for peripheral oedema and HF continue to confound clinical use of TZD medications, the direct cardiac effects of these drugs remain poorly understood and the clinical relevance of these clinical observations remains unclear. The present study will combine a series of state-of-the-art assessments to evaluate the cardiac effects of rosiglitazone treatment. (ClinicalTrials.gov NCT00424762).

Key Words: aerobic power • heart failure • myocardial triglyceride • rosiglitazone • thiazolidinedione

Diabetes and Vascular Disease Research, Vol. 6, No. 1, 43-50 (2009)
DOI: 10.3132/dvdr.2009.009


CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter    What's this?